News - Pfizer, Johnson & Johnson


Current filters:

PfizerJohnson & Johnson

Popular Filters

Bayer/Janssen's Xarelto poised to lead sales in VTE market: report


German drug major Bayer (BAYN: DE) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Xarelto (rivaroxaban)…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJanssenJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

Sales of psoriasis drugs to be worth $7.4 billion by 2020


The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

Xarelto and Eliquis set to displace current therapies in DVT/PE


Clinical data and the opinions of interviewed thought leaders indicate that there is little to distinguish…

BayerBristol-Myers SquibbCardio-vascularEliquisEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaPfizerPharmaceuticalXarelto

BioTrends views Xeljanz and Zytiga prescribing in USA


After around two months on the market, 37% of US rheumatologists have prescribed Pfizer's (NYSE: PFE)…

Anti-Arthritics/RheumaticsAstellas PharmaBiotechnologyJevtanaJohnson & JohnsonMedivationNorth AmericaOncologyPfizerPharmaceuticalSanofiXeljanzXtandiZytiga

Licensing deals for Philogen with Pfizer and GlycoVaxyn with Janssen


Privately held Italian biopharma firm Philogen SpA (Siena, Italy) has granted global drugs behemoth Pfizer…

BiotechnologyDekavilGlycoVaxynInflammatory diseasesJanssenJohnson & JohnsonLicensingPfizerPharmaceuticalPhilogenVaccines

Pain therapies sales to exceed $49 billion in 2026, driven by new product launches


The market for pain therapies will grow at an annual rate of 1.8% over the next 15 years, surpassing…

BiotechnologyfulranumabGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalTakeda Pharmaceuticalstanezumabtapentadol

Atrial fibrillation drug market will grow from $2.7 billion in 2011 to $9.2 billion in 2021


The atrial fibrillation drug market will experience dramatic growth over the next decade, increasing…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

ESMO 2012 Congress highlights


The European Society for Medical Oncology (ESMO) Congress kicked off in Vienna, Austria, last Friday…

GlaxoSmithKlineJanssenJohnson & JohnsonOncologyPazopanib TabletsPfizerPharmaceuticalResearchXalkoriZytiga

US surveyed PCPs and pain specialists experienced reimbursement restrictions for Janssen's Nucynta ER


The majority of US surveyed primary care physicians (PCPs) and pain specialists indicate that they have…

JanssenJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaNucyntaPfizerPharmaceuticalPricingtanezumab

J&J and Pfizer drop bapineuzumab development for Alzheimer's


There was disappointing - though not really unexpected - news yesterday for US health care giant Johnson…

bapineuzumabElanJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

Pfizer and Janssen's bapineuzumab fails to meet one Ph III study endpoints for Alzheimer's


US drugs behemoth Pfizer (NYSE: PFE) revealed yesterday that the co-primary clinical endpoints, change…

bapineuzumabJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

CHMP positive on first gene therapy, Glybera; and more opinions


Reversing an earlier negative opinion (The Pharma Letter April 22), the European Medicines Agency's Committee…

AdcetrisBiotechnologyCelgeneDacogenEuropeGlyberaIstodaxJanssen-CilagJohnson & JohnsonOncologyPfizerPharmaceuticalRare diseasesRegulationTakeda PharmaceuticalsuniQureXalkori

UK academia-pharma collaboration attracts £14.4 million funding


In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

Tapentadol ER has advantages over Lyrica in reducing diabetic neuropathy pain intensity


Surveyed US neurologists and managed care organization (MCO) pharmacy directors agree that reducing pain…

DepomedGraliseJohnson & JohnsonLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticaltapentadol

Outlook for VTE treatment and prophylaxis market


Driven primarily by the launches and strong uptake of oral anticoagulants, the combined markets for drugs…

BayerBristol-Myers SquibbCardio-vascularEliquisJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

Bayer’s Xarelto significantly reduced mortality in major ACS study; Bristol-Myers’ Eliquis fails endpoint in VTE trial


The US unit of Germany’s Bayer (BAY: DE) yesterday announced that the combination of oral Xarelto…

BayerBristol-Myers SquibbCardio-vascularEliquisJohnson & JohnsonPfizerPharmaceuticalResearchXarelto

Despite generics for two key drugs, neuropathic pain market will grow to $8.4 billion in 2020


The neuropathic pain drug market will experience modest growth over the next decade, increasing from…

Astellas PharmaEli LillyJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceutical

Sanofi to top Pfizer as number one for global pharma sales


French drug major Sanofi (Euronext: SAN) is expected to take the top spot amongst the world’s pharmaceuticals…

FinancialGlobalJohnson & JohnsonMarkets & MarketingMerck & CoMergers & AcquisitionsNovartisNovo NordiskPfizerPharmaceuticalSanofiTakeda PharmaceuticalsTeva Pharmaceutical Industries

Alzheimer’s drug market to triple to $14.3 billion by 2020, says DR


The Alzheimer’s disease drug market will nearly triple over the next 10 years, increasing from $5.4…

bapineuzumabEli LillyGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalsolanezumab

Back to top